ClinicalTrials.gg
Not yet recruitingNCT07856303Updated Oct 2, 2026

SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response

A Phase 2 interventional study of SHR-A1811 and Trastuzumab in HER2-positive Breast Cancer and Early Breast Cancer (EBC), sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing trastuzumab rezetecan in Breast Neoplasms — 46 open to participants now, 52 under way, 10 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
8th of 53
358 · median 111
Started
2026
with 20 others
Phase 2
34 of 53
34 open now
Primary completion
2032-08
later than 51 of 51 live
Registered
52nd of 53
by date
Lead sponsor
11 of 53
Fudan University

Among the 53 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 8th largest by planned enrollment, is one of 21 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 51 of the 51 other live ones, and was the 52nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

46 of the 53 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

41 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage IIB-IIIC HER2-positive early breast cancer who achieved pathologic complete response after neoadjuvant systemic therapy and have detectable postoperative circulating tumor DNA (ctDNA). Eligible participants will be randomized 1:1 and stratified by hormone receptor status, HER2 test category, and initial clinical anatomic stage. The primary endpoint is invasive disease-free survival.

Read the detailed description

Patients who have completed neoadjuvant systemic therapy and curative breast and axillary surgery with ypT0/is ypN0 disease will undergo postoperative ctDNA testing 14 to 42 days after the last definitive surgery and before initiation of adjuvant systemic therapy. Participants with ctDNA positivity and no clinical or radiographic evidence of recurrent or metastatic disease will be randomized to SHR-A1811 or trastuzumab plus pertuzumab. Post-randomization ctDNA results will not be used for clinical management and will remain blinded to investigators and participants until the primary analysis database is locked, unless a future ethics-approved protocol amendment specifies otherwise.

03

Conditions studied

  • HER2-positive Breast Cancer
  • Early Breast Cancer (EBC)

Keywords

  • Circulating Tumor DNA
  • ctDNA
  • Minimal Residual Disease
  • Pathologic Complete Response
  • Adjuvant Therapy
  • SHR-A1811
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written before any study-specific procedure and willingness to comply with study visits and sample collection.
  2. Female, aged 18 years or older.
  3. confirmed invasive breast carcinoma at initial diagnosis, without distant .
  4. -positive tumor at initial diagnosis, defined as IHC 3+ or IHC 2+ with ISH amplification; hormone receptor status must be known.
  5. Initial clinical anatomic stage IIB-IIIC according to the AJCC 8th edition.
  6. Completion of at least 6 cycles and at least 16 weeks of standard systemic therapy.
  7. Definitive breast surgery and appropriate axillary staging or dissection, with pathologically complete resection.
  8. Pathologic complete response, defined as no residual invasive carcinoma in the breast or regional lymph nodes (ypT0/is ypN0); residual ductal carcinoma in situ is permitted.
  9. Postoperative ctDNA positivity confirmed by the designated central testing laboratory 14-42 days after the last definitive surgery and before initiation of any adjuvant systemic therapy.
  10. No clinical, pathologic, or radiographic evidence of locoregional recurrence or distant metastasis before randomization; baseline chest CT is required to assess interstitial lung disease/noninfectious pneumonitis.
  11. Randomization within 12 weeks after the last definitive surgery; extension to 14 weeks may be permitted for documented surgical complications, reoperation, or sequential radiotherapy with principal investigator approval.
  12. performance status 0 or 1.
  13. at least 50% within 28 days before randomization, without cardiac dysfunction.
  14. Adequate bone marrow, hepatic, renal, and coagulation function.
  15. Negative pregnancy test for participants of and agreement to use highly effective for the protocol-specified period.

Exclusion criteria

Exclusion Criteria:

  1. Clinical, radiographic, or pathologic evidence of unresectable locally advanced, recurrent, or disease, or disease progression during therapy.
  2. Failure to achieve ypT0/is ypN0 or any residual invasive carcinoma in the breast or regional lymph nodes.
  3. Prior ipsilateral or contralateral breast cancer, including ductal carcinoma in situ; lobular carcinoma in situ is permitted.
  4. Any postoperative systemic anticancer therapy before randomization, including trastuzumab, pertuzumab, another anti- agent, chemotherapy, antibody-drug conjugate, or endocrine therapy; bridging therapy is not permitted.
  5. Prior neoadjuvant treatment with T-DM1, trastuzumab deruxtecan, SHR-A1811, or another HER2-directed antibody-drug conjugate.
  6. Prior or current interstitial lung disease/noninfectious pneumonitis requiring treatment, active interstitial lung disease on screening imaging, pulmonary fibrosis, severe , resting hypoxemia, or another pulmonary disorder that would interfere with pulmonary toxicity assessment.
  7. Clinically significant cardiovascular disease, including symptomatic heart failure or class II-IV heart failure, myocardial infarction or unstable angina within 6 months before screening, uncontrolled clinically significant arrhythmia, greater than 470 ms, or blood pressure above 150/90 mmHg despite appropriate treatment.
  8. Active or uncontrolled infection requiring systemic treatment, or active / or not meeting protocol and institutional control criteria.
  9. Toxicities from prior therapy not recovered to grade 1 or lower, except alopecia, hyperpigmentation, and stable grade 2 peripheral neuropathy judged clinically insignificant by the investigator.
  10. Another within 5 years before screening, except adequately treated basal or squamous cell skin cancer, cervical carcinoma in situ, or another malignancy with a low risk of recurrence.
  11. Severe to a study drug or any of its .
  12. Pregnancy, breastfeeding, or plans for pregnancy during the protocol-specified period.
  13. Any serious medical or psychosocial condition that, in the investigator's judgment, would make study treatment, follow-up, or interpretation of results unsafe or unreliable.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
358 participants (estimated)

Study arms

  • Experimental
    SHR-A1811

    Participants will receive SHR-A1811 4.8 mg/kg by intravenous infusion once every 3 weeks for 14 cycles. Dose interruption and reduction will be managed according to the protocol and study drug management instructions.

    Drug: SHR-A1811

  • Active comparator
    Trastuzumab Plus Pertuzumab

    Participants will receive trastuzumab plus pertuzumab once every 3 weeks. Including treatment received during the neoadjuvant period, the total perioperative duration of dual HER2-targeted therapy will be approximately 1 year.

    Drug: Trastuzumab · Drug: Pertuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Invasive Disease-Free Survival (IDFS)

    IDFS is defined as the time from randomization to the first occurrence of ipsilateral invasive breast tumor recurrence, regional invasive recurrence, distant recurrence, contralateral invasive breast cancer, secondary invasive primary cancer (nonbreast), or death from any cause.

    Time frame: At 3 years after randomization

Secondary outcomes

  1. Distant Disease-Free Survival (DDFS)

    DDFS is defined as the time from randomization to the first occurrence of distant recurrence, secondary invasive primary cancer (nonbreast), or death from any cause.

    Time frame: Up to 5 years after randomization

  2. Overall Survival (OS)

    Time from randomization to death from any cause.

    Time frame: Up to 5 years after randomization

  3. Brain Metastasis-Free Interval (BMFI)

    Time from randomization to brain metastasis

    Time frame: Up to 5 years after randomization

  4. Treatment-Emergent Adverse Events

    Number and percentage of participants with treatment-emergent adverse events and serious adverse events, graded according to NCI CTCAE version 5.0.

    Time frame: From randomization through 40 days after the last dose of study treatment

07

Study locations

1 site
  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2032, 70 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 70 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Aug 2032
CompletionEst.
Aug 2034
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856303
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Director, Fudan University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Aug 2032 (estimated)
Completion
Aug 2034 (estimated)
Last update
Oct 2, 2026

Study contacts

Zhimin Shao
Contact
zhimingshao@yahoo.com
86-021-64175590 ext. 8888

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion